Exhibit 2.1

AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER

THIS AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of February 4, 2025, is entered into by and among, RAFAEL HOLDINGS, INC., a Delaware corporation (“Parent”), TANDEM THERAPEUTICS, INC., a Nevada corporation and a wholly-owned subsidiary of Parent (“First Merger Sub”), TANDEM THERAPEUTICS, LLC, a Nevada limited liability company and a wholly-owned subsidiary of Parent (“Second Merger Sub”), and CYCLO THERAPEUTICS, INC., a Nevada corporation (the “Company”).

RECITALS

WHEREAS, Parent, First Merger Sub, Second Merger Sub and the Company are parties to an Agreement and Plan of Merger, dated as of August 21, 2024, and an Amendment to Agreement and Plan of Merger, dated as of December 18, 2024 (as so amended, the “Merger Agreement”);

WHEREAS, the Merger Agreement provides that it may terminate or be terminated in certain circumstances including by either Parent or the Company if the Merger shall not have been consummated by the End Date; and

WHEREAS, the parties have agreed to extend the End Date of the Merger Agreement from February 15, 2025 to March 31, 2025 as set forth below.

Capitalized terms used but not defined in this Amendment have the meanings set forth in the Merger Agreement.

NOW, THEREFORE, for and in consideration of the mutual premises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

AGREEMENTS

1. Amendment. The Merger Agreement shall be amended to revise the definition of “End Date” therein to read as follows: “End Date” shall mean March 31, 2025.”

2. Continuing Effectiveness of the Merger Agreement. Except to the extent amended hereby, the Merger Agreement and all terms, conditions and provisions thereof shall continue in full force and effect in all respects.

3. Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one and the same instrument.

4. Miscellaneous. This Amendment shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to conflicts of laws principles.

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered as of the date first written above.

COMPANY:	CYCLO THERAPEUTICS, INC.


	By:
	Name: N. Scott Fine
	Title: Chief Executive Officer



PARENT:	RAFAEL HOLDINGS, INC.


	By:
	Name: William Conkling
	Title: Chief Executive Officer



FIRST MERGER SUB:	TANDEM THERAPEUTICS, INC.


	By:
	Name: David Polinsky
	Title: President



SECOND MERGER SUB:	TANDEM THERAPEUTICS, LLC


	By:
	Name: David Polinsky
	Title: Authorized Person

[Signature Page to Amendment No. 2 to Agreement and Plan of Merger]

Cyclo Therapeutics, Inc. 8-K